Member Info for CHELSEA7

29/11/2018 15:33 24,406 8.17
29/11/2018 10:36 12,086 8.17
29/11/2018 08:56 4,500 7.82

Amazing they can insult anybody really, they have been very wrong so far.

Have a good day and weekend,

Good or not.....................1.20/1.25

Not sure what catagory it falls in, but ten years to go commercial is normal once Patents are granted. Yes there is some protection, will find out more, ATB

Noise, pretty sure the Patent holder is protected by time limits from date of Approval?

Bye fourteen. What a tragic loss for the BB.

Totally agree, as ever.

Inan, I don2t agree with Wigwammer on that either, that thinking could apply to any of the contestants. If anything Scancell winning just backs up CRUKs confidence in backing us. Just IMHO

By your own admission you were on the naughty step for constantly suggesting you have inside information from VAL themselves which is available to all who phone them.

The BB IMHO has been a better place without a few of you ramping away,

Likewise Tommy, just would prefer not to buy more TBH.

LD is our biggest asset, still at our helm, that is pretty key for me.

Well there is hardly a rush at 8-10p.

Doesn"t really matter for me, there is a fair amount of inflection news to come, just a case of waiting now for New Year.

The GC is one big bonus and i don"t know anybody who has brought in solely for it.

Far too soon after the AGM for whinging about news, so well done for trying to stimulate some debate.

We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.



The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.

​

We also firmly believe that by putting our clients first, we create long term value for all stakeholders.

​

Now that MiFID II has come into effect you will be delighted to know that, whether you are an asset manager or a private investor, all can continue to receive Trinity Delta research notes. Our research is paid for by our corporate clients and we do not carry out any execution business. We do and will continue to make it freely available to all investors via multiple platforms (Trinity Delta and MiFID II).

​

Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).

Really not sure, just looking actually. Seems to cover only a few companies, maybe it is just a better deal. I had been wondering why we suddenly dropped out of Hardman. Hopefully this year coming, we might earn a few updates?

http://docs.wixstatic.com/ugd/07354c_b3b393d919ad412aabb576db17467d6a.pdf

Same template as Hardman Research, that answers a couple of questions.

Thanks Deadly, night guys.

Would be nice to hear about SCIB2 too.

I dream of both.

Especially at my age!!!

Chester, the 69 is probably wishful thinking, lol.

Wishful thinking, lol.